Kevin Tang, a director and 10% owner of Boundless Bio, Inc. (NASDAQ:BOLD), filed a Form 4 on November 17, 2026, disclosing two open-market purchases of common stock totaling 13,812 shares made on November 13 and November 17, 2026.

Key Highlights

  • First purchase: 1,395 shares of common stock acquired on November 13, 2026, at a weighted-average price of $2.40 per share.
  • Second purchase: 12,417 shares acquired on November 17, 2026, in multiple transactions at prices ranging from $2.39 to $2.40 per share, at a weighted-average price of $2.40.
  • Resulting ownership: Following the November 17 transaction, the reporting persons beneficially owned 3,049,379 shares of common stock, held indirectly.
  • Ownership structure: Shares are held across four entities: Tang Capital Partners, LP (691,177 shares), Tang Capital Partners International, LP (988,434 shares), Tang Capital Partners III, Inc. (691,170 shares), and Tang Capital Partners IV, Inc. (678,598 shares).
  • Relationship: Kevin Tang is identified as a director and 10% owner of Boundless Bio; he is the sole manager of Tang Capital Management, LLC, which serves as general partner of TCP and TCPI, and the sole director and CEO of TCP III and TCP IV.
  • Indirect ownership: All beneficial ownership reported is indirect, with Kevin Tang holding a pecuniary interest in shares held by the four Tang Capital entities.

Tang Capital Entities Accumulate Boundless Bio Shares Across Two Trading Days

According to the Form 4 filing, Kevin Tang and Tang Capital Management, LLC jointly reported two purchases of Boundless Bio, Inc. common stock. The first transaction, dated November 13, 2026, involved the acquisition of 1,395 shares at a weighted-average price of $2.40, bringing indirectly held beneficial ownership to 3,036,962 shares. The filing states that all shares in the first transaction were purchased at exactly $2.40.

The second transaction, dated November 17, 2026, covered the purchase of 12,417 shares at prices ranging from $2.39 to $2.40, with a weighted-average price of $2.40 per share, raising total indirect beneficial ownership to 3,049,379 shares. The filing notes that the reporting persons will provide, upon request, the number of shares purchased at each individual price within the stated range.

The filing identifies Tang Capital Management, LLC as the general partner of Tang Capital Partners, LP and Tang Capital Partners International, LP, with Kevin Tang serving as the sole manager of that LLC. Tang Capital Partners III, Inc. and Tang Capital Partners IV, Inc. are described as indirectly wholly owned by TCP, with Kevin Tang serving as sole director and Chief Executive Officer of each. All reported beneficial ownership is classified as indirect, with Kevin Tang holding a pecuniary interest in shares held across all four entities. No derivative securities transactions were reported.

What Was Disclosed

Kevin Tang and Tang Capital Management, LLC disclosed two purchases of Boundless Bio common stock on November 13 and November 17, 2026, totaling 13,812 shares at weighted-average prices of $2.40, resulting in indirect beneficial ownership of 3,049,379 shares held across four affiliated entities.